Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock. (Q34370297)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18839141%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

title

Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18839141%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

0 references

0 references

0 references

1 reference

placebo-controlled trial

1 reference

1 reference

corrigendum / erratum

Erratum to: Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock.

0 references

author

Ivor S Douglas

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18839141%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Andrew Rhodes

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18839141%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1

Simon Finfer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18839141%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

author name string

V Marco Ranieri

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18839141%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

B Taylor Thompson

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18839141%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Philip S Barie

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18839141%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Jean-François Dhainaut

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18839141%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Bengt Gårdlund

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18839141%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

John C Marshall

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18839141%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

publication date

7 October 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18839141%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

published in

Intensive Care Medicine

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18839141%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

volume

34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18839141%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18839141%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

page(s)

1935-1947

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18839141%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00134-008-1266-6

15 January 2020

exact match

0 references

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2995439

Human recombinant activated protein C for severe sepsis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2995439

The outcome of patients with sepsis and septic shock presenting to emergency departments in Australia and New Zealand.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2995439

Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2995439

Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2995439

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2995439

Surviving sepsis--practice guidelines, marketing campaigns, and Eli Lilly

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2995439

Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2995439

Drotrecogin alfa (activated): does current evidence support treatment for any patients with severe sepsis?

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2995439

Randomized trials stopped early for benefit: a systematic review

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2995439

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2995439

Sources of variability on the estimate of treatment effect in the PROWESS trial: implications for the design and conduct of future studies in severe sepsis.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2995439

Severe sepsis epidemiology: sampling, selection, and society

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2995439

Pharmaceutical industry sponsorship and research outcome and quality: systematic review

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2995439

The epidemiology of sepsis in the United States from 1979 through 2000

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2995439

Assessing the use of activated protein C in the treatment of severe sepsis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2995439

Risks and benefits of activated protein C treatment for severe sepsis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2995439

Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2995439

Efficacy and safety of recombinant human activated protein C for severe sepsis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2995439

Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2995439

Ethical issues in stopping randomized trials early because of apparent benefit.

6 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00134-008-1266-6

Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2995439

The Surviving Sepsis guidelines: evidence-based ... or evidence-biased?

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2995439

When (not) to stop a clinical trial for benefit.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2995439

Activated protein C: do more survive?

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2995439

Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2995439

Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2995439

Be skeptical about unexpected large apparent treatment effects: the case of an MRC AML12 randomization.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2995439

Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2995439

The Italian SEPSIS study: preliminary results on the incidence and evolution of SIRS, sepsis, severe sepsis and septic shock

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2995439

Epidemiology of severe sepsis in critically ill surgical patients in ten university hospitals in China

27 October 2018

1 reference

12 December 2020

Use of recombinant human activated protein C in patients with severe sepsis: a French retrospective multicentre study

1 reference

12 December 2020

Can we RESOLVE the treatment of sepsis?

1 reference

12 December 2020

1 reference

12 December 2020

Incidence, treatment, and outcome of severe sepsis in ICU-treated adults in Finland: the Finnsepsis study

1 reference

12 December 2020

Severe sepsis--a new treatment with both anticoagulant and antiinflammatory properties

1 reference

12 December 2020

Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment*

1 reference

12 December 2020

Drotrecogin alfa (activated) in sepsis: initial experience with patient selection, cost, and clinical outcomes

1 reference

12 December 2020

Prescription of rh-APC differs substantially among western European countries

1 reference

12 December 2020

Use of drotrecogin alfa (activated) for severe sepsis in New Jersey acute care hospitals

1 reference

12 December 2020

Activated protein C (Xigris) treatment in sepsis: a drug in trouble

1 reference

12 December 2020

10.1007/S00134-008-1266-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18839141%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18839141%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference